Spyre Therapeutics, Inc. (SYRE) Return on equity 2016–2025
Spyre Therapeutics, Inc. (SYRE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-21.7%FY2025 · since FY2016: -34.5% → -21.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -21.7% | +18.5 pp |
| FY2024 | -40.2% | +143.9 pp |
| FY2023 | -184.1% | -17.5 pp |
| FY2022 | -166.6% | -88.2 pp |
| FY2021 | -78.4% | -20.5 pp |
| FY2020 | -57.9% | +72.4 pp |
| FY2019 | -130.2% | -64.5 pp |
| FY2018 | -65.8% | -11.7 pp |
| FY2017 | -54.1% | -19.6 pp |
| FY2016 | -34.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice